Benchmark Research | Sacramento, CA

Research site

(Unclaimed)

Location

4345 Arden Way, Sacramento, California, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

EYE201

EYE103

Peramivir

Fluticasone Proprionate

Ritonavir

Lubiprostone

Ulipristal Acetate

Ciprofloxacin

Olopatadine

Parent organization

This site is a part of Benchmark Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 34 total trials

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study w...

Enrolling

BRVO - Branch Retinal Vein Occlusion

Diabetic Macular Edema (DME)

Drug: EYE201

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult...

Enrolling

Encephalitis

Biological: MVA-BN-WEV

Other: Placebo

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BAROLO)

EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo